Anti-resorptive therapy is the principal means of treating osteoporotic disorders. The two families of presently available anti-resorptive drugs, namely bisphosphonates and denosumab, dampen activity of osteoclasts by reducing their number. In consequence, these agents also arrest bone remodelling eventuating suppressed formation as well as resorption. Evidence exists that osteoclasts recruit osteoblasts to sites of bone remodelling by mobilizing chemotactic proteins from matrix and direct secretion of such proteins that attract osteoblast precursors. Thus, anti-resorptive agents, such as the cathepsin K inhibitor odanacatib, that dampen osteoclast function but not number may also preserve osteoblast recruitment by preserving the bone resorptive cell.

Original languageEnglish
Pages (from-to)ii61-ii63
JournalRheumatology (United Kingdom)
StatePublished - 2016


  • Bone formation
  • Bone remodelling
  • Odanacatib
  • Osteoclast formation
  • Osteoclast function


Dive into the research topics of 'Therapeutic implications of suppressing osteoclast formation versus function'. Together they form a unique fingerprint.

Cite this